Affinity Asset Advisors »

Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Karyopharm Therapeutics Inc note 3.000%10/1

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics Inc note 3.000%10/1 held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics Inc note 3.000%10/1 by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $13M 15M 0.82
2025-06-30 $12M 15M 0.76
2025-03-31 $12M 15M 0.76
2024-12-31 $12M 15M 0.78
2024-09-30 $9.6M 12M 0.79
2024-06-30 $6.3M 9.8M 0.65

More positions owned by Affinity Asset Advisors

Insmed Com Par $.01 (INSM)
Verona Pharma Sponsored Ads (VRNA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)
Abivax Sa Sponsored Ads (ABVX)
Mineralys Therapeutics (MLYS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Merus N V (MRUS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Lexeo Therapeutics (LXEO)

View all positions for Affinity Asset Advisors

Top funds holding Karyopharm Therapeutics Inc note 3.000%10/1

Affinity Asset Advisors
Opaleye Management
Exome Asset Management
BLB^B Advisors
Jpmorgan Chase & Co

View all funds holding Karyopharm Therapeutics Inc note 3.000%10/1